- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03327987
Early Flu Shots in SOT
October 16, 2020 updated by: University Health Network, Toronto
Safety and Immunogenicity of Influenza Vaccine During the First Post-Transplant Year in Solid Organ Transplant Recipients
Although time from transplant has been a factor in vaccine response, there is limited data on immunizations that occur in the first post-transplant year, and there are no data that suggest influenza vaccination early post-transplant may have any adverse effects on the graft.
It is suggested that early vaccinations may lead to reduced immunogenicity due to induction immunosuppression.
However, not vaccinating patients may leave them vulnerable to influenza infection for a period of time.
This study is designed to look at the immunogenicity and side effects of the standard of care influenza vaccine in patients between 31 and 365 days post-transplant.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
Influenza virus is an important cause of morbidity in the transplant population and can lead to viral and bacterial pneumonia.
Influenza vaccine is effective in the prevention of influenza infection and is recommended by the Canadian National Advisory Committee on Immunization (NACI).
The annual influenza vaccine is suggested for transplant patients as the standard of care starting from 3 months post-transplant.
Most recent guidelines now suggest that it is reasonable to get a flu shot starting earlier at 1 month post-transplant.
Anti-rejection drugs are now tapered more quickly and it is possible that antibodies will be produced against the flu shot as early as 1 month post-transplant.
The study hypothesizes that kidney and liver transplant recipients in the early post-transplant period (31-180 days) will have similar immunogenicity as those in the late post-transplant period (>180 days).
Study Type
Observational
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G2N2
- University Health Network, Toronto General Hospital, Multi-Organ Transplant
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Adult solid organ transplant recipients between 31 and 365 days post-transplant.
Description
Inclusion Criteria:
- Kidney, liver or pancreas transplant recipients on at least one immunosuppressive medication
- Age ≥ 18
- Outpatient status
- Greater than 30 days post-transplant
Exclusion Criteria:
- Has already received influenza vaccination for 2017-2018 season
- Egg allergy or allergy to previous influenza vaccine
- Febrile illness in the past one week
- Active Cytomegalovirus viremia
- Use of Rituximab in the past one year
- Ongoing or recent (in past 30 days) therapy for acute rejection
- Chronic kidney insufficiency (creatinine clearance ≤30mL/min or dialysis-dependent
- Previous life-threatening reaction to influenza vaccine (i.e., Guillain Barre Syndrome)
- Receipt of intravenous immunoglobulin (IVIG) in the past 30 days or planning to receive IVIG in the next four weeks
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
31-90 days
Patient 31-90 days after transplantation receiving standard of care annual 2017-2018 influenza vaccine.
|
The standard of care annual 2017-2018 influenza vaccine will be used for this study.
Other Names:
|
91-180 days
91-180 days after transplantation receiving standard of care annual 2017-2018 influenza vaccine.
|
The standard of care annual 2017-2018 influenza vaccine will be used for this study.
Other Names:
|
181-365 days
181-365 days after transplantation receiving standard of care annual 2017-2018 influenza vaccine.
|
The standard of care annual 2017-2018 influenza vaccine will be used for this study.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Vaccine immunogenicity
Time Frame: 4 weeks
|
Vaccine immunogenicity based on assessment of pre- and post-vaccine (4 weeks) antibody titer. A positive vaccine response will be defined based on:
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety- adverse events
Time Frame: 7 days
|
Local and systemic adverse events to vaccination
|
7 days
|
Safety- graft rejection
Time Frame: 6 months
|
Rates of biopsy proven allograft rejection in the 6 months following vaccination
|
6 months
|
Safety- HLA
Time Frame: 4 weeks
|
Development of de novo or increased titer of HLA alloantibody and specifically DSA (donor specific antibody).
The 4 weeks post-vaccine sample will be compared with the pre-vaccine samples.
|
4 weeks
|
Vaccine efficacy- CMI
Time Frame: 4 weeks
|
Analysis of CMI in a subgroup of 60 patients (influenza strain-specific CD4+ and CD8+ T-cell responses; detectable vs. non-detectable and absolute percentage) at four weeks post-vaccine vs. pre-vaccine sample.
CMI responses will also be correlated with HAI responses.
|
4 weeks
|
Vaccine efficacy- infection
Time Frame: 6 months
|
Documented influenza infection (i.e., microbiology proven by the direct fluorescent antibody, viral culture, or PCR) in the six months following vaccination.
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Deepali Kumar, MD, UHN
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 7, 2019
Primary Completion (Actual)
May 7, 2019
Study Completion (Actual)
May 7, 2019
Study Registration Dates
First Submitted
October 27, 2017
First Submitted That Met QC Criteria
October 27, 2017
First Posted (Actual)
November 1, 2017
Study Record Updates
Last Update Posted (Actual)
October 20, 2020
Last Update Submitted That Met QC Criteria
October 16, 2020
Last Verified
October 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 17-5960
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Influenza
-
Novartis VaccinesCompletedInfluenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza VirusBelgium
-
Gamaleya Research Institute of Epidemiology and...CompletedInfluenza A | Influenza A Virus Infection | Influenza Epidemic | Influenza H5N1Russian Federation
-
Vanderbilt University Medical CenterHuman Vaccines ProjectCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Influenza Type B | Influenza A H3N2 | Influenza A H1N1United States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza | Influenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...National Institutes of Health (NIH)CompletedInfluenza AUnited States
Clinical Trials on standard of care influenza vaccine
-
Marshfield Clinic Research FoundationCenters for Disease Control and PreventionCompleted
-
Oriol ManuelUniversity of Zurich; University Hospital, Geneva; University Hospital, Basel... and other collaboratorsCompletedInfluenza | Organ TransplantationSwitzerland, Spain
-
Sanofi Pasteur, a Sanofi CompanyRecruitingInfluenza ImmunizationUnited States, Puerto Rico
-
Sanofi Pasteur, a Sanofi CompanySuspended
-
Hospital Israelita Albert EinsteinMinistry of Health, BrazilCompletedAcute Coronary SyndromeBrazil
-
Brigham and Women's HospitalPatient-Centered Outcomes Research Institute; National Heart, Lung, and Blood... and other collaboratorsCompletedMyocardial Infarction | Heart FailureUnited States, Canada, Puerto Rico
-
University of PittsburghSanofi Pasteur, a Sanofi CompanyCompleted
-
University of NottinghamNorthumbria UniversityCompleted
-
Vanderbilt UniversityCompletedPediatric Patients With Acute Lymphoblastic LeukemiaUnited States
-
University of Wisconsin, MadisonCompletedInflammatory Bowel Disease (IBD)United States